DocG DocG | AI-Powered Clinical Summaries
← DocG Medical Summaries

Top Pulmonology/Respirology Research Papers

Live ranking — trailing 6 months, each paper's latest score Scores fold Pulmonology / Respirology Relevance & Applicability into the quality dimensions; papers scored before the dynamic-specialty rubric keep their original score Showing the top 10 of 348 ranked articles — sign in free for the full ranking and per-criterion score breakdowns
1. 7.8
Efficacy and safety of gabapentin for treatment of cough in idiopathic pulmonary fibrosis: a randomized, double-blinded, placebo-controlled clinical trial.
Overall: This small but rigorous randomized trial found a large, patient-important improvement in IPF-related cough with an accessible treatment, offset by increased adverse effects and a need for broader confirmation.
2. 7.5
Efficacy of Antiinflammatory Therapies for Adults With Non-Cystic Fibrosis Bronchiectasis: A Systematic Review and Network Meta-Analysis.
Overall: A strong synthesis of randomized evidence demonstrates clinically meaningful exacerbation reductions with limited reported harms, but direct impact on routine US primary care is moderated by the specialist-oriented population and treatment context.
3. 7.2
Discriminative performance and clinical utility of chronic obstructive pulmonary disease exacerbation categories for predicting future exacerbations.
Overall: Large, consistent cohorts support a simple two-year risk category, but its ability to improve patient outcomes remains untested.
4. 7.2
Azithromycin for Preschoolers with Wheezing in the Emergency Department.
Overall: A strong multicenter randomized trial found no symptomatic or utilization benefit from azithromycin, offering clear evidence to reduce unnecessary antibiotic treatment for acute preschool wheezing.
5. 7.1
Astegolimab for chronic obstructive pulmonary disease with frequent exacerbations: pooled analysis of the ALIENTO and ARNASA trials.
Overall: Astegolimab modestly reduced clinically important COPD exacerbations in two large, well-controlled trials, but missing absolute effects and the burden of frequent biologic injections temper its immediate practice impact.
6. 7.1
Effectiveness of the Adjuvanted Respiratory Syncytial Virus Prefusion F3 Vaccine in Preventing Major Adverse Cardiovascular Events and Severe Exacerbations of COPD and Asthma Among US Adults ≥ 60 Years of Age.
Overall: This large US observational study links RSV vaccination to fewer serious cardiovascular and pulmonary events, but absent absolute effects and safety data plus residual confounding limit certainty about its net clinical impact.
7. 7.0
Dupilumab in chronic obstructive pulmonary disease: a pooled analysis of emergency department visits, hospital admissions, and systemic corticosteroid use.
Overall: Two large randomized trials show meaningful reductions in acute-care use among selected patients with eosinophilic COPD, although missing absolute effects, safety results, and treatment-burden details temper the clinical impact.
8. 7.0
Association of Inhaling Marijuana With Asthma Attacks: An Analysis of Nationally Representative Survey Data.
Overall: This nationally representative longitudinal study provides clinically relevant evidence supporting avoidance counseling for inhaled marijuana among adults with asthma, but self-reported observational data and absent absolute risks limit certainty.
9. 6.9
First- and Second-Year Outcomes After Nirsevimab Immunization.
Overall: This large observational study shows consistent, clinically important first-year protection against RSV hospitalization with a simple intervention, but modest absolute benefit, possible adverse associations, residual confounding, and no second-year protection limit its impact.
10. 6.9
Prognostic impact of single moderate exacerbation in COPD patients: Analysis of 12-year mortality and future exacerbation risk.
Overall: This prospective cohort supports treating a single moderate COPD exacerbation as prognostically important, but it does not establish that changing management based on this classification improves patient outcomes.
Score Guide: 9-10 Exceptional 7-8 Strong 5-6 Moderate 3-4 Weak 1-2 Poor

Get the top Pulmonology/Respirology papers in your inbox

Free 300-word clinical summaries 3× per week, plus the full ranking of all 348 recent Pulmonology/Respirology papers with per-criterion AI score breakdowns.

Sign Up Free